Inactive Instrument

AXCA HEALPAR

Equities

AXLA

US05454B2043

Axcella Therapeutics Announces That Laurent Chardonnet to Depart as Chief Financial Officer, Effective November 28, 2021

November 10, 2021 at 07:58 am EST

Axcella Therapeutics announced that Chief Financial Officer Laurent Chardonnet will be departing the company for personal reasons and to pursue other interests, effective November 28, 2021. Chardonnet plans to continue to serve as a consultant to the company to ensure a smooth transition.

Latest news about AXCA HEALPAR

North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	Dec. 19	DJ
North American Morning Briefing : Traders Eye -2-	Dec. 12	DJ
North American Morning Briefing : China Outlook Downgrade Jolts Mood	Dec. 05	DJ
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report	Nov. 28	DJ
Axcella Health Inc.(NasdaqGM:AXLA) dropped from S&P TMI Index	Nov. 28	CI
Axcella Health Inc.(OTCPK:AXLA) dropped from NASDAQ Composite Index	Nov. 23	CI
North American Morning Briefing : All Eyes on -2-	Nov. 21	DJ
Investors Look Forward to Fed Minutes, Economic Data as Exchange-Traded Funds, Equity Futures Rise Marginally Pre-Bell	Nov. 20	MT
Top Premarket Decliners	Nov. 20	MT
Axcella Health Inc. Announces Chief Executive Officer Changes	Nov. 01	CI
Axcella Health Inc. Appoints Craig R. Jalbert as Principal Financial Officer	Nov. 01	CI
Axcella Health Inc. Announces Management Changes	Nov. 01	CI
Axcella Health Sinks Premarket Wednesday, Shares Poised for Ninth Decline in 10 Days Following Reverse Stock Split	23-09-27	MT
Axcella Health Slips Premarket Friday, Poised for Seventh Consecutive Day of Declines After Announcing Reverse Stock Split	23-09-22	MT
Correction: --Axcella Health Slumped 8.1% in Premarket Activity Thursday After Sinking 15% in Previous Regular Trading Session	23-09-21	MT
Axcella Health Slumped 8.1% in Premarket Activity Wednesday After Sinking 15% in Previous Regular Trading Session	23-09-21	MT
Top Midday Decliners	23-09-15	MT
Axcella Health to Implement 1-for-25 Reverse Stock Split -- Shares Dive After-Hours	23-09-14	MT
Sector Update: Health Care Stocks Rising Late Afternoon	23-08-29	MT
Sector Update: Health Care	23-08-29	MT
Top Midday Gainers	23-08-29	MT
Axcella Health Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Axcella Health Inc. Announces Resignation of Margaret Koziel as Senior Vice President and Chief Medical Officer	23-06-29	CI
Axcella Health Inc.(NasdaqGM:AXLA) dropped from Russell Microcap Index	23-06-23	CI
Axcella Health Inc.(NasdaqGM:AXLA) dropped from Russell Microcap Growth Index	23-06-23	CI

Chart AXCA HEALPAR

Duration

Period

More charts

Company Profile

Axcella Health Inc. is a clinical-stage biotechnology company. The Company is focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with simultaneously impacting multiple biological pathways. Its pipeline includes lead therapeutic candidates for the treatment of Long COVID (also known as Post-COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC)) associated fatigue, and the treatment of non-alcoholic steatohepatitis (NASH). AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1125 is an oral product candidate that contains six amino acids and derivatives.

Sector

More about the company